Literature DB >> 16376525

Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam.

Florence Loiseau1, Claudine Le Bihan, Michel Hamon, Marie-Hélène Thiébot.   

Abstract

The anxiolytic potential of melatonin and agomelatine, a potent MT(1/2) receptor agonist, and their combined effects with diazepam, were investigated in rats using the punished drinking test, the safety signal withdrawal operant paradigm, the elevated-plus-maze and hypophagia-induced novelty. In the punished drinking test, evening injections of melatonin (80 mg/kg, IP, but not 20 and 40 mg/kg) and agomelatine (40 mg/kg, IP) increased the number of foot shocks received. However, neither melatonin (40-80 mg/kg) nor agomelatine (20-40 mg/kg) released response suppression during the period associated with the safety signal withdrawal and affected rats' behaviour in the elevated-plus-maze. Furthermore, agomelatine (40 mg/kg) did not enhance food consumption in unfamiliar environment. However, the co-administration of melatonin (80 mg/kg) or agomelatine (20-40 mg/kg) with diazepam, at a dose (0.25 mg/kg) inactive on its own, induced an anxiolytic-like effect in the punished drinking test and the elevated plus-maze. These results indicate that, although mostly devoid of anxiolytic-like action per se, melatonin and agomelatine can potentiate the anxiolytic effects of diazepam.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16376525     DOI: 10.1016/j.euroneuro.2005.11.007

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  9 in total

1.  Exogenous daytime melatonin modulates response of adolescent mice in a repeated unpredictable stress paradigm.

Authors:  Adejoke Yetunde Onaolapo; Ajibola Nurudeen Adebayo; Olakunle James Onaolapo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-11-14       Impact factor: 3.000

2.  A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation.

Authors:  Michele Fornaro; Davide Prestia; Salvatore Colicchio; Giulio Perugi
Journal:  Curr Neuropharmacol       Date:  2010-09       Impact factor: 7.363

Review 3.  Novel pharmacological treatments for generalized anxiety disorder: Pediatric considerations.

Authors:  A Irem Sonmez; Ammar Almorsy; Laura B Ramsey; Jeffrey R Strawn; Paul E Croarkin
Journal:  Depress Anxiety       Date:  2020-05-17       Impact factor: 6.505

4.  Abnormal Hippocampal Melatoninergic System: A Potential Link between Absence Epilepsy and Depression-Like Behavior in WAG/Rij Rats?

Authors:  Slavianka Moyanova; Antonio De Fusco; Ines Santolini; Roberta Celli; Domenico Bucci; Federica Mastroiacovo; Giuseppe Battaglia; Ferdinando Nicoletti; Jane Tchekalarova
Journal:  Int J Mol Sci       Date:  2018-07-06       Impact factor: 5.923

Review 5.  Anxiolytic properties of compounds that counteract oxidative stress, neuroinflammation, and glutamatergic dysfunction: a review.

Authors:  Patrícia Santos; Ana P Herrmann; Elaine Elisabetsky; Angelo Piato
Journal:  Braz J Psychiatry       Date:  2018-10-11       Impact factor: 2.697

6.  Central depressant and nootropic effects of daytime melatonin in mice.

Authors:  Olakunle J Onaolapo; Adejoke Y Onaolapo; Akanni A Abiola; Eniafe A Lillian
Journal:  Ann Neurosci       Date:  2014-07

Review 7.  Melatoninergic System in Parkinson's Disease: From Neuroprotection to the Management of Motor and Nonmotor Symptoms.

Authors:  Josiel Mileno Mack; Marissa Giovanna Schamne; Tuane Bazanella Sampaio; Renata Aparecida Nedel Pértile; Pedro Augusto Carlos Magno Fernandes; Regina P Markus; Rui Daniel Prediger
Journal:  Oxid Med Cell Longev       Date:  2016-10-18       Impact factor: 6.543

8.  Indirect autonomic nervous system activity assessment with heart rate variability in rats with cyclophosphamide-induced hemorrhagic cystitis treated with melatonin or agomelatine.

Authors:  Łukasz Dobrek; Agnieszka Baranowska; Piotr J Thor
Journal:  Contemp Oncol (Pozn)       Date:  2015-06-30

Review 9.  Neuroinflammation and the Immune-Kynurenine Pathway in Anxiety Disorders.

Authors:  Yong-Ku Kim; Sang Won Jeon
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.